Cochrane · systematic review · CD009716
Multiple versus fewer antiplatelet agents for preventing early recurrence after ischaemic stroke or transient ischaemic attack
Naqvi, IA, Kamal, AK, Rehman, H · Cochrane Database of Systematic Reviews · 2020 · Cochrane Library
StrokeAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
16
current version
GRADE rated
14
No studies
2
Included studies
NR
No studies 2 · 12.5%Ungraded 0 · 0%Very low 0 · 0%Low 2 · 12.5%Moderate 6 · 37.5%High 6 · 37.5%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Multiple compared to fewer antiplatelet agents for preventing early recurrence after ischaemic stroke or transient ischaemic attack
Population: preventing early recurrence after ischaemic stroke or TIA
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Outcomes at ≥ 3 months Multiple vs fewer antiplatelet agents | no estimate extracted | NR | No studies |
Stroke Multiple vs fewer antiplatelet agents | RR 0.73 [0.66, 0.82] | 14 studies · 16707 participants | Moderate Downgraded: risk of bias |
Vascular death Multiple vs fewer antiplatelet agents | RR 0.98 [0.67, 1.45] | 11 studies · 15901 participants | Moderate Downgraded: risk of bias |
Myocardial infarction Multiple vs fewer antiplatelet agents | RR 1.38 [0.63, 2.99] | 3 studies · 11411 participants | High |
Stroke, myocardial infarction, or vascular death Multiple vs fewer antiplatelet agents | RR 0.72 [0.64, 0.82] | 7 studies · 12932 participants | Moderate Downgraded: risk of bias |
Intracranial haemorrhage Multiple vs fewer antiplatelet agents | RR 1.92 [1.05, 3.5] | 6 studies · 14287 participants | Low Downgraded: risk of bias |
Extracranial haemorrhage Multiple vs fewer antiplatelet agents | RR 2.14 [1.79, 2.57] | 7 studies · 10658 participants | High |
Ischaemic stroke Multiple vs fewer antiplatelet agents | RR 0.73 [0.64, 0.83] | 3 studies · 13121 participants | High |
Dual compared to one antiplatelet agent for preventing early recurrence after ischaemic stroke or transient ischaemic attack
Population: preventing early recurrence after ischaemic stroke or TIA
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Outcomes at ≥ 3 months Dual vs one antiplatelet agent | no estimate extracted | NR | No studies |
Stroke Dual vs one antiplatelet agent | RR 0.71 [0.62, 0.8] | 13 studies · 13637 participants | Moderate Downgraded: risk of bias |
Vascular death Dual vs one antiplatelet agent | RR 0.84 [0.54, 1.3] | 10 studies · 12831 participants | Moderate Downgraded: risk of bias |
Myocardial infarction Dual vs one antiplatelet agent | RR 1.38 [0.63, 2.99] | 3 studies · 11411 participants | High |
Stroke, myocardial infarction, or vascular death Dual vs one antiplatelet agent | RR 0.72 [0.64, 0.82] | 7 studies · 12932 participants | Moderate Downgraded: risk of bias |
Intracranial haemorrhage Dual vs one antiplatelet agent | RR 1.53 [0.76, 3.06] | 5 studies · 11217 participants | Low Downgraded: risk of bias |
Extracranial haemorrhage Dual vs one antiplatelet agent | RR 3.08 [1.74, 5.46] | 6 studies · 7586 participants | High |
Ischaemic stroke Dual vs one antiplatelet agent | RR 0.7 [0.61, 0.81] | 2 studies · 10051 participants | High |